CoChat

Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy

Yang, Qicheng, Mamounas, Michael, Yu, Gang, Kennedy, Scott, Leaker, Brian, Merson, James, Wong-Staal, Flossie, Yu, Mang, Barber, Jack R. · 1998 · Human Gene Therapy
Cited by 127

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Recombinant adenoassociated virus (rAAV) type 2 vectors have been used to transduce a wide variety of cell types, including hematopoietic progenitor cells. For in vivo gene transfer, it is desirable to have an rAAV vector that specifically transduces selected target cells. As a first step toward generating an rAAV vector capable of targeting delivery in vivo, we have engineered a chimeric protein combining the AAV capsid protein and the variable region of a single-chain antibody against human CD34 molecules, a cell surface marker for hematopoietic stem/progenitor cells. Inclusion of the chimeric CD34 single-chain antibody–AAV capsid proteins within an rAAV virion significantly increased the preferential infectivity of rAAV for the CD34+ human myoleukemia cell line KG-1, which is normally refractory to rAAV transduction. Antibodies against the single-chain antibody and the CD34 protein blocked this transduction. This chimeric vector represents a significant improvement in the host range of rAAV and the first step toward specific gene delivery by rAAV vectors to cells of choice, in this case, hematopoietic progenitor cells, for the treatment of human disease. We have constructed rAAV type 2 vectors encoding modified capsid proteins that allow for cell-type specific targeting to cells that express the CD34 protein. Specifically, a fusion protein was constructed, consisting of the N terminus of the AAV virion protein, VP2, and a single-chain antibody directed against CD34. Vector particles packaged in the presence of the VP2–antibody fusion protein are bound specifically to CD34-expressing KG-1 cells. Moreover, while KG-1 cells were resistant to transduction by unmodified rAAV vectors, the modified vector particles were able to transduce these cells. Antibodies against either the CD34 molecule or the single-chain antibody blocked the modified rAAV virion trasduction of KG-1 cells. Although improvements in titer of these cell type-specific targetable vectors will be necessary before implementation in in vivo gene therapy, this work demonstrates that the tropism of the rAAV particle can be altered by addition of chimeric capsid fusion proteins during viral particle formation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1998.9.13-1929

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 127

Metadata

Authors
Yang, Q., Mamounas, M., Yu, G., Kennedy, S., Leaker, B., Merson, J., Wong-Staal, F., Yu, M., & Barber, J. R.
Venue
Human Gene Therapy
Published
1998-09
Volume
9
Issue
13
Pages
1929-1937
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2009792531
Cited by
127
References
2
FWCI
3.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy. https://app.cochat.ai/papers/10.1089/hum.1998.9.13-1929
The paper
Yang, Q., Mamounas, M., Yu, G., Kennedy, S., Leaker, B., Merson, J., Wong-Staal, F., Yu, M., & Barber, J. R. (1998). Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy. Human Gene Therapy. https://doi.org/10.1089/hum.1998.9.13-1929

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.